Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Advertisement

Advertisement

Feb

23

Today In Oncology

First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers

CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax

Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

Advertisement

© 2026 HSP News Service, L.L.C.